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Abstract
Background: The development of evidence-based clinical practice guidelines has gained wide acceptance in high-
income countries and reputable international organizations. Whereas this approach may be a desirable standard,
challenges remain in low-income settings with limited capacity and resources for evidence synthesis and guideline
development. We present our experience using the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach for the recent revision of the Kenyan pediatric clinical guidelines focusing on
antibiotic treatment of pneumonia.
Methods: A team of health professionals, many with minimal prior experience conducting systematic reviews,
carried out evidence synthesis for structured clinical questions. Summaries were compiled and distributed to a
panel of clinicians, academicians and policy-makers to generate recommendations based on best available research
evidence and locally-relevant contextual factors.
Results: We reviewed six eligible articles on non-severe and 13 on severe/very severe pneumonia. Moderate
quality evidence suggesting similar clinical outcomes comparing amoxicillin and cotrimoxazole for non-severe
pneumonia received a strong recommendation against adopting amoxicillin. The panel voted strongly against
amoxicillin for severe pneumonia over benzyl penicillin despite moderate quality evidence suggesting clinical
equivalence between the two and additional factors favoring amoxicillin. Very low quality evidence suggesting
ceftriaxone was as effective as the standard benzyl penicillin plus gentamicin for very severe pneumonia received a
strong recommendation supporting the standard treatment.
Conclusions: Although this exercise may have fallen short of the rigorous requirements recommended by the
developers of GRADE, it was arguably an improvement on previous attempts at guideline development in low-
income countries and offers valuable lessons for future similar exercises where resources and locally-generated
evidence are scarce.
The approach to developing clinical practice guidelines
has become increasingly formal over the last two decades.
Requirements now span rigor in evidence appraisal to
incorporation of user preferences. As a result developed
countries have invested substantially in national institutes
to develop guidelines (National Institute for Health and
Clinical Excellence [1],; Agency for Healthcare Research
and Quality [2], Norwegian Knowledge Centre for the
Health Services [3] etc). The World Health Organization
(WHO), after criticisms of its guideline development pro-
cedures [4], recently adopted the Grading of Recommen-
dations Assessment, Development and Evaluation
(GRADE) approach [5] expecting it to be used for all new
technical advice [6]. Some of the challenges of using
GRADE or similar structured approaches to guideline
development at international and national levels in devel-
oped economies are emerging [7,8]. However, reports
documenting experiences from low-income settings are
lacking. Yet the GRADE approach, acknowledging that
evidence alone is inadequate for making recommenda-
tions, specifically directs that local contextual factors be
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This has resulted in more transparently developed gui-
dance than in the past, where guideline development
usually took the form of a small meeting of experts
behind closed doors. However the price of this has been
increasingly formal procedures making new demands on
limited national capacity.
In 2009 the Kenyan Ministry of Medical Services
requested support to revise the national pediatric guide-
lines. We decided, with limited technical and financial
resources, to attempt the use of the GRADE approach
(see summary in Table 2) for this national exercise.
Here we illustrate, from the perspective of those review-
ing, summarizing and presenting the evidence in a
resource-constrained setting, challenges encountered
during this process and when moving from evidence to
recommendations. In doing this we seek to go beyond
the current focus on further improvements in metho-
dology [9] and broaden the discussion to questions
around implementation of GRADE procedures in low
income settings. Although we attempted to tackle ele-
ven guideline-related questions we focus here, as an
exemplar, on questions identified when attempting to
update the case-management guideline for pneumonia
in children.
Background to childhood pneumonia guidelines
Childhood pneumonia continues to rank as the leading
cause of hospitalization and d e a t hi nc h i l d r e ng l o b a l l y
[10]. The current Kenyan guidelines (Table 1) for anti-
biotic treatment of community-acquired childhood
pneumonia are adapted from those of WHO and recom-
mend classification of children into one of 3 clinical
categories of severity to guide decisions on appropriate
treatment [11]. Key treatment recommendations for
children without HIV infection are largely unchanged
since their first launch over twenty years ago and con-
cerns have been expressed over their current and future
appropriateness [12]. Perhaps linked to such concerns
there is evidence of poor guideline adherence revealing
possible preferences for ‘stronger’ (broader spectrum,
non-beta-lactam) antibiotics [13].
GRADE, GRADE-lite or an inability to make the GRADE?
When resources are limited compromises are made. We
illustrate such compromises here both to indicate where
sharing resources, capacity and prior work may be help-
ful and because they raise the question of whether or
not what we describe, as an illustration of what may be
possible in low income settings, is a ‘GRADE-compliant’
process.
Defining the clinical questions and relevant outcomes
Our task was updating of pediatric national guidelines in
a period of 9 months. In a recent report an international
guideline development group engaged an extensive net-
work of experts taking into account multidisciplinary
expertise, and regional and gender representation to
determine policy-relevant questions [14]. Such an elabo-
rate process was not possible in our case. Policy relevant
questions were thus based on the scope of prior guide-
lines, working knowledge of topic areas and observed
local clinical practice, discussions with a small number of
key-informants in government and ap r i o r iconsidera-
tions of what might be feasible. Similarly, we defined
within the ‘GRADE-team’ predominantly critical out-
comes (mortality and morbidity) that spanned all guide-
line topics under review. This approach was used to help
standardize procedures and in anticipation of presenta-
tion and discussion with a national recommendations
panel likely to have limited experience considering
research evidence. PICO (Population, Intervention, Com-
parator, Outcome) formatted questions (Table 2) were
thus constrained from the outset by a modest set of opi-
nions from those within the GRADE-team and local
observations. This was in large part driven by limited
resources and an absence of mechanisms to rapidly gain
wider opinions from key sources including patients, care-
givers and policy makers. Although this relatively narrow
focus has the potential for introducing bias such
Table 1 2005 GoK clinical classification and recommended antibiotic treatment of children with cough and/or
difficulty breathing
Syndrome Clinical criteria Recommended antibiotic treatment
Non-severe
pneumonia
Rapid breathing:
(≥ 50 if 2 - 11 months)
(≥ 40 if 12 - 59 months)
Out patient with oral cotrimoxazole
Severe
pneumonia
lower chest indrawing and HIV-unexposed Inpatient treatment with IV/IM benzyl penicillin monotherapy)
Very severe
pneumonia
Unable to drink, central cyanosis, altered level of
consciousness, head nodding, grunting and HIV-exposed
Inpatient treatment with IV/IM benzyl penicillin) and gentamicin
combination therapy OR IV/IM chloramphenicol) (plus high dose
cotrimoxazole, 8 mg/kg trimethoprim and 40 mg/kg of
sulfamethoxazole 6 hourly I.V/oral if HIV-exposed)
GoK - Government of Kenya
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term in settings like Kenya.
We defined the following clinical questions regarding
antibiotic treatment for children aged 2 - 59 months
with non-severe, severe and very severe pneumonia:
1. For children with non-severe pneumonia, should
cotrimoxazole be replaced by amoxicillin?
2. For children with severe pneumonia, should benzyl
penicillin be replaced by oral amoxicillin?
3. For children with severe pneumonia, should benzyl
penicillin monotherapy be replaced by benzyl penicillin
plus gentamicin?
4. For children with very severe pneumonia, should
chloramphenicol be abandoned as an alternative treat-
ment to benzyl penicillin plus gentamicin?
5 .F o rc h i l d r e nw i t hv e r ys e v e r ep n e u m o n i a ,s h o u l db e n -
zyl penicillin plus gentamicin be replaced by ceftriaxone?
Children exposed to, or infected with HIV and those
with severe acute malnutrition were excluded from our
population of interest due to the unique treatment con-
siderations among these groups.
Bases for the clinical questions
The decision to review clinical questions 1 and 4 was
based on recent WHO technical updates. These recom-
mend the use of amoxicillin in favor of cotrimoxazole in
regions with high resistance to cotrimoxazole and benzyl
penicillin plus gentamicin in preference to chloramphe-
nicol for very severe pneumonia [15]. Evidence from
Asian studies suggesting comparable effectiveness of
oral amoxicillin and benzyl-penicillin for treatment of
severe pneumonia led us to review clinical question 2.
Widespread use of benzyl penicillin plus gentamicin and
ceftriaxone among Kenyan clinicians for the treatment
of severe and very severe pneumonia respectively, con-
trary to the recommended guidelines [13], prompted
our choice of clinical questions 3 and 5.
Evidence retrieval, assessment and synthesis
Our approach to literature searching and summary are
outlined in Table 3 and Figure 1. The technical and
human resource capacity for accessing literature and for
undertaking systematic reviews in low-income country set-
tings, while slowly improving, remains limited. In an effort
to ensure a participatory process and despite the absence
of ‘professional’ guideline developers, we engaged govern-
ment pediatricians in the review process. This meant for
all topics, including pneumonia, that only 2 reviewers
independently appraised available literature, reaching con-
sensus by discussion where required. In some cases
reviewer pairs had very similar professional backgrounds
and very limited experience in literature appraisal although
206 articles identified in 
PubMed 
8 articles identified in The 
Cochrane Library 
206 articles identified after duplicates removed 
206 articles screened  
(Abstracts read) 
16 full-text articles assessed 
for eligibility 
14 articles included in 
qualitative analysis 
6 articles included in meta-
analyses‡ 
190 articles excluded 
2 Full-text articles excluded† 
† Two studies recruited HIV-exposed / infected children 
‡ Two studies included in each meta-analysis for clinical questions 1, 2 and 4 
Figure 1 Flow diagram of search strategy used for selecting studies for review.
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vided over the 8 months preparation phase (Figure 2).
However, further investment in quality assurance of the
review process was beyond the resources and capacity of
the group, making errors or misjudgments possible, per-
haps particularly when examining topics without existing
well conducted systematic reviews. Despite our focus on
the major killers of children including pneumonia, malaria,
neonatal sepsis and malnutrition, absence of systematic
reviews was common and where reviews were available
none had GRADE summary of evidence tables (with
searches up to March 2010).
Grading the quality of evidence
Of the 14 team members involved in the entire process
only 2 (ME and NO) had experience conducting
systematic reviews and limited, prior exposure to the
GRADE approach. However, supported by one key team
member (NO), software developed by the GRADE
Working Group was utilized to classify the quality of
a v a i l a b l ee v i d e n c ei n t of o u rc a t e g o r i e s( T a b l e2 )a f t e r
upgrading and downgrading based on our perceptions
of merits and weaknesses respectively. As has been
pointed out elsewhere [7] there are no absolute criteria
for up and down-grading decisions and while GRADE
helps make the process explicit the decisions remain to
a degree subjective. Where possible, we conducted
meta-analyses to improve the precision around esti-
mated effects using RevMan version 5 (Cochrane Colla-
boration) and subsequently presented the combined
data in the GRADEpro software [16]. The meta-analyses
included all randomized controlled trials reporting
1. Establishment of guideline development group / evidence summary reviewers 
2. Guideline development meetings (basic training on critical appraisal / evidence synthesis, GRADE 
provided in the form of two 1 day workshops and intermittent personal consultations) 
3. Clinical question definition and discussion on patient-important outcomes resulting in development of 
concise PICO format clinical questions 
4. Systematic literature search, abstraction of data and study characteristics from publications, appraisal 
of evidence quality, preparation of GRADE evidence profiles, mini-reviews and key point summaries. 
Progress updates thorough individual pair and group meetings 
5. Meeting with expert panel to incorporate contextual factors / discuss draft recommendations. 
a) Expert panel 
provided with 
evidence reviews, 
GRADE tables and 
key point summaries 
a day before the 
discussion 
b) 45 minute 
presentation, question 
and answer session 
with the panel 
focused entirely on 
the evidence 
c) One and a half 
hour facilitated 
discussion on 
additional factors and 
how these might 
influence 
recommendations 
d) Voting using an 
adaptation of GRADE 
grid  for each question:  
-2 (strong 
recommendation 
against) 
0 (no preference)  
+2 (strong 
recommendation for) 
Figure 2 Steps in the development of the revised 2010 Kenyan pediatric treatment guidelines.
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controlled trials.
We now illustrate some of the challenges we found in
making these decisions in the case of pneumonia. Before
d o i n gt h i sw ep r o v i d eav e r yc o n c i s es u m m a r yo ft h e
primary evidence for selected questions with their
GRADE quality of evidence tables. Our full evidence
summary, that is entirely consistent with a recently pub-
lished systematic review (that does not include GRADE
tables) [17] can be accessed online [18].
The evidence
We searched online databases, PubMed and The
Cochrane Library using a common search strategy dis-
played in Table 3 to identify randomized controlled
trials (RCTs) relevant to our questions of interest. The
Therapy category and Narrow scope options under the
Clinical Queries filter were applied within PubMed.
Figure 1 illustrates the process used to select the studies
we considered for review.
Non-severe pneumonia
For the policy question “should cotrimoxazole be
replaced by amoxicillin in Kenyan children aged 2 - 59
months fulfilling the WHO criteria for non-severe
pneumonia?” our search (see Table 3) retrieved 30
publications. Of the 6 eligible articles shortlisted, three
were reviews, Kabra et al 2006 (Cochrane) [19] -
updated in 2010 [17], Ayieko et al 2007 [20] and Grant
et al 2009 [21] and three randomized controlled trials
[22-24]. None of the trial data reported mortality as a
primary outcome. The estimated effect of the interven-
tion on treatment failure in all three trials was similar
to that among children receiving the standard treat-
ment. The quality of evidence from all three studies
was downgraded for indirectness with respect to the
populations studied since all were conducted in Asia
(two in Pakistan [22,23] and one in India [24]). No ser-
ious limitations, inconsistencies or imprecision were
identified in the studies reviewed, resulting in a con-
clusion of moderate quality evidence suggesting no dif-
ference between the two treatments. Our GRADE
evidence summary for these studies is presented in
Table 4.
Severe pneumonia
Among children with severe pneumonia we sought to
address the following questions:
Table 2 Summary of the GRADE system for guideline development
We used the GRADE system to develop the recommendations since it provides an explicit and transparent assessment of the quality of evidence
and the strength of recommendations for clinical questions.
PICO, an acronym that represents four attributes (Population, Intervention, Comparator and Outcome) is widely used in formulation of clinical
questions. The PICO elements for our 5 clinical questions of interest for childhood pneumonia in the Kenyan treatment guidelines are given below.
Population: Kenyan children aged 2 - 59 months
meeting WHO criteria for:
Intervention (proposed new
treatment)
Comparator (standard
treatment)
Outcomes of interest
i. non-severe pneumonia I. Amoxicillin Co-trimoxazole i. Mortality
ii. severe pneumonia. (HIV-unexposed without
severe malnutrition)
II. Amoxicillin Benzyl penicillin/ampicillin ii. Treatment failure
III. Benzyl penicillin/ampicillin
plus gentamicin
Benzyl penicillin (or
amoxicillin)
OR
iii. very severe pneumonia. (HIV-unexposed without
severe malnutrition)
IV. Benzyl penicillin/ampicillin
plus gentamicin
Chloramphenicol Time to resolution of signs
of pneumonia
V. Ceftriaxone Benzyl penicillin/ampicillin
plus gentamicin
iii. Cost
GRADE classifies quality of evidence into four categories (high, moderate, low, or very low) and recommendations (for or against treatments) into
two grades (strong or weak). With study design as the starting point, RCTs ranking highest and observational studies lowest, it allows for
downgrading of the quality of evidence in the presence of factor related to study limitations, consistency, directness and publication bias. It also
allows for upgrading the quality of evidence in the presence of large treatment effects, a dose-response gradient and residual confounding likely to
underestimate the true effect. The current revised interpretation of the GRADE levels of evidence is shown below.
Quality level Interpretation
High Highly confident that the true effect lies close to that of the estimate of the effect
Moderate Moderately confident in the effect estimate: The true effect is likely to be close to the
estimate of the effect, but there is a possibility that it is substantially different
Low Limited confidence in the effect estimate: The true effect may be substantially different from
the estimate of the effect
Very low Very little confidence in the effect estimate: The true effect is likely to be substantially
different from the estimate of effect
Unlike other guideline development tools, GRADE uniquely separates judgments on the quality of evidence and the strength of recommendations -
recognizing that making recommendations involves tradeoffs between benefits and harms, and contextual factors (e.g. costs, baseline risk of population,
clinician values and preferences, etc). Thus, using the above assessments, we classified recommendations into categories summarized in figure 2.
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oral amoxicillin?
2) Should injectable benzyl penicillin monotherapy be
replaced by benzyl penicillin plus gentamicin?
We identified 8 articles including 2 Cochrane systema-
tic reviews that addressed the two questions.
(a) Antibiotic treatment of severe pneumonia: benzyl
penicillin/ampicillin versus amoxicillin
Three trials compared oral versus parenteral treatment
for severe pneumonia: Addo-Yobo et al [17,20,25,26]
conducted a large multi-centre trial of 1702 children in
Colombia, Ghana, India, Mexico, Pakistan, South Africa
(two sites), Vietnam, and Zambia while Atkinson et al
[17,26,27] recruited 203 children with radiologically-con-
firmed community acquired pneumonia in the UK and
Hazir et al [17,28] studied 2100 Pakistani children. All
three trials, supported by a meta-analysis of the results of
the studies by Hazir et al and Addo-Yobo et al which
showed a pooled risk ratio of treatment failure for the
two studies of 0.97, 95% CI 0.83 - 1.14, suggested equiva-
lence of the two treatments. Since the studies were con-
ducted among predominantly non-African populations
t h eq u a l i t yo fe v i d e n c ew a sd o w n g r a d e db yo n el e v e lf o r
indirectness. The evidence was therefore graded as mod-
erate quality suggesting equivalence comparing benzyl
penicillin and amoxicillin (Table 5).
(b) Antibiotic treatment of severe pneumonia: benzyl
penicillin/ampicillin monotherapy versus benzyl penicillin/
ampicillin and gentamicin
Only one small trial was found comparing costs and clin-
ical outcomes enrolling 40 children with severe pneumo-
nia in Malaysia in 1999/2000 after randomization to
either benzyl penicillin/ampicillin monotherapy or com-
bination therapy with gentamicin [17,29]. The results of
this trial showed no differences in clinical outcome
between the two treatments and higher costs associated
with the combination of ampicillin and gentamicin.
Very severe pneumonia
Two policy questions were addressed relating to antibio-
tic treatment of children with very severe pneumonia:
1) Should chloramphenicol be abandoned as an alter-
native treatment to benzyl penicillin plus gentamicin?
2) Should benzyl penicillin plus gentamicin/chloram-
phenicol be replaced by ceftriaxone?
Two trials reviewed addressed each of the two ques-
tions. The studies were also summarized in a Cochrane
review [17].
(c) Antibiotic treatment of very severe pneumonia:
chloramphenicol versus benzyl penicillin/ampicillin and
gentamicin
Two trials compared the effectiveness of benzyl penicil-
lin/ampicillin combined with gentamicin versus chloram-
phenicol for very severe pneumonia. Duke et al (2002)
studied 1116 children in Papua New Guinea [17,20,30]
while Asghar et al (2008) recruited 958 children from
eight sites in seven developing countries [17,31]. A meta-
analysis of the two studies yielded a pooled risk ratio of
treatment failure of 0.79, 95% CI 0.66 - 0.94 in favor of
penicillin/ampicillin plus gentamicin.
(d) Antibiotic treatment of very severe pneumonia: benzyl
penicillin/ampicillin and gentamicin versus ceftriaxone
We found no experimental data directly comparing out-
comes following treatment of very severe childhood
pneumonia using the recommended antibiotics against
ceftriaxone, a common regimen used by clinicians in
Kenya. One small trial (n = 97) from Turkey compared
benzyl penicillin combined with chloramphenicol and
ceftriaxone at day 10 of treatment for radiologically-con-
firmed severe and very severe pneumonia [17,32] while
another small trial (n = 71) compared intravenous benzyl
penicillin combined with gentamicin with intravenous
amoxicillin-clavulanate in Indian children [17,33] with
severe hypoxemic pneumonia. Neither trial reported a
superior regimen. Failure to report on the process of ran-
domization and allocation concealment in the study con-
ducted in Turkey was considered a serious limitation and
therefore the evidence was graded downwards by one
level. This quality of evidence was further downgraded
on account of serious indirectness of population and
comparison as well as imprecision. The evidence from
the study conducted in India was also graded downwards
for indirectness of population and comparison and
imprecision. The overall quality of evidence was regarded
to be very low addressing the question of whether
Table 3 Search strategy for clinical questions for pneumonia
We searched PubMed and the Cochrane Library. Both free text and MeSH terms were used in the PubMed search as shown below.
Search strategy: pneumonia AND (child* OR paediatric OR pediatric) AND (antibiotic OR co-trimoxazole OR cotrimoxazole OR sulfamethoxazole OR
sulphamethoxazole OR penicillin OR amoxicillin OR amoxycillin OR cephalosporin OR ceftriaxone OR gentamicin OR chloramphenicol OR quinolone* OR
levofloxacin OR macrolide* OR erythromycin).
Systematic reviews and randomized controlled trials relevant our questions of interest were reviewed. Where none were available, observational
studies were considered. The search was not limited by date or language. In addition, bibliographies of eligible articles were screened for additional
reports warranting inclusion. Abstracts for all retrieved articles were read and the full text articles for those addressing the policy question of interest
selected. Searches around the 3 broad policy questions were conducted in February 2010 and the results reviewed independently by A.A. and M.E.
We then summarized the evidence from the retrieved literature for each policy question in the form of mini-reviews and key finding summaries (all
available at http://www.idoc-africa.org).
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cin (Table 6).
Grading the evidence
The primary evidence retrieved was from randomized
controlled trials and therefore might initially be consid-
ered high in quality. However, after subjecting the stu-
dies to the GRADE quality assessment process, all the
studies were graded downwards leaving no high quality
evidence for any of our 5 Kenyan policy questions.
Although the GRADE system provides for the inclusion
of data from observational studies, we found none that
addressed our clinical questions. Our reasons for down-
grading evidence, and any challenges with this are high-
lighted below.
Limitations
Limitations that might result in downgrading are reason-
ably clearly defined in GRADE and include lack of alloca-
tion concealment, absence of blinding and large losses to
follow up. For pneumonia two trials failed to report allo-
cation concealment [29,32] and blinding was only
achieved in the trials comparing cotrimoxazole versus
amoxicillin, likely due to practical limitations related to
the nature of the interventions in the other trials (e.g.
comparisons between injectable versus oral treatments
[25,27,28]). Reported losses to follow up were low in all
of the identified studies. Despite the global importance of
pneumonia as a cause of mortality in children [34] evi-
dence was often inadequate in quantity or quality or
both, a finding common to most other topic areas we
examined.
Inconsistencies
Inconsistency refers to large and unexplained variability
in magnitude of effects across studies. Hidden inconsis-
tency becomes more apparent as the number of studies
compared increases. With only a few studies available
apparent inconsistency was only detected in one instance,
Table 4 GRADE evidence profile 1: Cotrimoxazole versus amoxicillin for non-severe pneumonia
†
Quality assessment Summary of findings
Number of patients Effect Quality of
evidence
No of studies/
Design
Limitations Inconsistency Indirectness Imprecision Amoxicillin Cotrimoxazole Odds ratio
(95% CI)
Outcome 1: Treatment failure based on clinical signs. Follow-up 2 - 5 days.
Importance: Critical
2 RCTs [22,23] no serious
limitations
no serious
inconsistency
serious
1 no serious
imprecision
3
147/922
(15.9%)
231/1132
(20.4%)
0.83 (0.65 -
1.07)
Moderate
Outcome 2: Treatment failure based on clinical signs. Follow-up 4-6 days.
Importance: Critical
1 cluster
randomised trial [24]
no serious
limitations
no serious
inconsistency
serious
2 no serious
imprecision
3
137/993
(13.8%)
97/1016 (9.5%) 1.52 (0.73 -
3.17)
Moderate
Outcome 3: Mortality
Importance: Critical
No studies - - - - - - - -
Outcome 4: Cost
Importance: Important
No studies - - - - - - - -
Overall quality of evidence: Moderate quality evidence suggests no difference between standard and proposed treatments for outcomes
assessed
Benefits or desired
effects:
Amoxicillin may be also effective for treatment of severe pneumonia, potentially simplifying treatment by reducing severity
classes to two.
Risks or undesired
effects
Potential for increased bacterial resistance to amoxicillin with widespread use. Reduced options for second line treatment in
case of treatment failure - a whole new class of antibiotic might have to be provided as second line treatment.
Values and
preferences:
Cotrimoxazole is formulated as a commonly used tablet in adults too that can be divided for children if pediatric formulations
are missing - the same is not true for amoxicillin that is often distributed as capsules if syrups are not available
Costs: Amoxicillin is more costly than cotrimoxazole (US$ 0.12 and US$ 0.21 for cotrimoxazole and amoxicillin syrups respectively for
a course appropriate for a child weighing approximately 10 kg [KEMSA* July 2009])
Feasibility Both drugs are widely available and in use
† Clinical question: For Kenyan children aged 2 - 59 months who meet WHO criteria for non-severe pneumonia, should cotrimoxazole be replaced by amoxicillin?
1 Indirectness of population (studies conducted in Pakistan)
2 Indirectness of population (study conducted in India)
3 Although studies failed to show a difference between the two treatments, narrow confidence intervals and power calculation described by authors supported
decision against downgrading the quality for imprecision.
KEMSA - Kenya Medical Supplies Agency
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non-severe pneumonia. Straus et al [22] reported super-
iority of amoxicillin over cotrimoxazole with other stu-
dies [23,24] reporting equivalence. Although this trial
appeared to influence the conclusions of an influential
review suggesting amoxicillin should be the preferred
treatment [21] the effect appeared due to the inclusion of
a group of children with severe pneumonia. We, there-
fore, did not downgrade the quality of evidence but
instead opted to consider evidence from only those chil-
dren with non-severe pneumonia, a decision which
resulted in three reports indicating equivalence of these
drugs in children with only non-severe pneumonia.
Indirectness
Indirectness refers to differences between the evidence
under review and the clinical question of interest in rela-
tion to the PICO elements. We downgraded all the stu-
dies reviewed by one level for indirectness of population
based on geographic location since they included little or
no data from African children. This subjective decision
was based on studies suggesting higher risks of treatment
failure and mortality in African children with pneumonia
[31,35,36]. Interestingly, this position was shared by the
Kenyan audience who cited professional experiences to
back their distrust of the generalizability of data from
Asia. Indirectness was also related to the interventions
studied and resulted in downgrading the evidence avail-
able for treating very severe pneumonia [32,33], where
this, coupled with only data from non-African popula-
tions led us to downgrade for indirectness alone by two
levels. Amongst other topics we found we also down-
graded evidence on the basis that data were relatively old,
were available only or predominantly on adults or dealt
with outcomes other than those pre-specified as critical.
Imprecision
In studies where sample size is small and number of
events few, estimated effects are associated with wide
confidence intervals and therefore regarded as imprecise.
Table 5 GRADE evidence profile 2: Benzyl penicillin versus amoxicillin for severe pneumonia
†
Quality assessment Summary of findings
Number of patients Effect Quality of
evidence
No of studies/
Design
Limitations Inconsistency Indirectness Imprecision amoxicillin benzyl
penicillin
Odds ratio
(95% CI)/P value
Outcome 1: Treatment failure based on clinical signs. Assessed at 48 hours [25]and 5 days [28]
Importance: Critical
2 RCTs [25,28] no serious
limitations
no serious
inconsistency
serious
1 no serious
imprecision
244/1882
(13.0%)
248/1857
(13.4%)
0.97 (0.80-1.17) Moderate
Outcome 2: Time to resolution of signs of pneumonia
Importance: Critical
1 RCT [27] no serious
limitations
no serious
inconsistency
serious
2 no serious
imprecision
100
(1.3 days)
†
103
(1.3 days)
†
P = 0.001 for
equivalence
Moderate
Outcome 3: Mortality
Importance: Critical
No studies - - - - - - - -
Outcome 4: Cost
Importance: Important
No studies - - - - - - - -
Overall quality of evidence: Moderate quality evidence suggests that the two treatments are equivalent for outcomes
assessed
Benefits or
desired effects
Safety of oral over injectable treatments, convenient dosing schedule (twice daily for amoxicillin versus four times a day for
benzyl penicillin)
Risks or undesired
effects
None identified
Values and
preferences
Painless oral administration for amoxicillin preferable to injectable route required for benzyl penicillin/ampicillin, Mothers like
injections; Mothers would not stay in hospital for oral medications; Staff would not feel they were giving a strong enough
treatment for a severe disease
Costs Potential reduction in cost of resources required for injectable treatment including the option of out-patient management
Feasibility Both antibiotics widely available and in use
† Clinical question: For HIV-unexposed Kenyan children aged 2 - 59 months without clinical signs of severe malnutrition who meet WHO criteria for severe
pneumonia, should parenteral benzyl penicillin/ampicillin be replaced by inpatient oral amoxicillin?
1 Indirectness of population (one study conducted in Pakistan, one multicentre, multi-country)
2 Indirectness of population (study conducted in the UK among children with radiologically confirmed pneumonia)
†Median duration to resolution of signs of pneumonia
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recruited less than 100 patients graded downwards by
one level for imprecision [29,32,33].
Our ability to conduct meta-analysis incorporating data
from all of the studies reviewed was frustrated by differ-
ences in reported outcomes [27] or an inability to incorpo-
rate data from a large cluster randomized controlled trial
[24] (because entry of primary data assumes individual
randomization) into a pooled analysis in GRADEpro.
Publication Bias
Reliance only on published studies may cause bias if there
is a preference for reporting only ‘positive’ outcomes. Our
resources and we suspect those of many in low income set-
tings, precluded detailed searches of grey literature making
such a bias likely, particularly where there are already very
few published trials. In the case of pneumonia the similar-
ity of studies to those identified in a subsequently
published Cochrane review [17] are reassuring but for
other topics this remains a threat to our findings.
Additional evidence
We did not find any studies reporting on cost-effectiveness
of alternative pneumonia treatments. We considered that
evidence from observational studies suggesting no clinical
difference following treatment of pneumonia in children
with beta-lactam antibiotics in the presence of penicillin-
resistant or penicillin-sensitive pneumococci [37] to be of
potential value when considering recommendations. How-
ever, local data on in vitro resistance and the clinical effec-
tiveness of antibiotic treatments were either limited or
completely lacking respectively.
Moving from evidence to recommendations
The GRADE approach indicates that contextual factors
including cost, local values and preferences, feasibility,
undesired effects and benefits should be taken into
Table 6 GRADE evidence profile 3: Benzyl penicillin plus gentamicin versus ceftriaxone for very severe pneumonia
†
Quality assessment Summary of findings
Number of patients Effect Quality of
evidence
No of studies/
Design
Limitations Inconsistency Indirectness Imprecision ceftriaxone benzyl penicillin and
gentamicin
(P
value)
Outcome 1: Time to resolution of signs and symptoms of pneumonia
Importance: Critical
1 RCT [32] serious
1 no serious
inconsistency
very serious
2 serious
3 51 46 (P >
0.05)
Very low
Outcome 2: Treatment failure/time to resolution of clinical signs of pneumonia
Importance: Critical
1 RCT [33] no serious
limitations
no serious
inconsistency
very serious
4 Serious
5 33 38 (P >
0.1)
Very low
Outcome 3: Mortality
Importance: Critical
No studies - - - - - - - -
Outcome 4: Cost
Importance: Important
No studies - - - - - - - -
Overall quality of evidence: Very low quality evidence suggests no advantage of ceftriaxone over benzyl penicillin/ampicillin and
gentamicin
Benefits or
desired effects
Lower risks, less discomfort associated with single injection
Risks or undesired
effects
Potential emergence of extended spectrum beta-lactamase (ESBL)-producing organisms; concern of ‘overuse’ of important
second line drug and what next if it doesn’t work?
Values and
preferences
Favourable once-daily dosing schedule
Costs Ceftriaxone more costly than penicillin/gentamicin. However availability of cheap generic preparations and additional costs
(consumables and human resource) associated with multiple injections may outweigh apparent cost disadvantage of ceftriaxone.
Feasibility Ceftriaxone already widely available and in use
† Clinical question: For HIV-unexposed Kenyan children aged 2 - 59 months without clinical signs of severe malnutrition who meet WHO criteria for very severe
pneumonia, should benzyl penicillin/ampicillin plus gentamicin be replaced by ceftriaxone?
1 Limitation due to failure to lack of description of randomisation/allocation concealment
2 Indirectness of comparison (compared penicillin chloramphenicol versus ceftriaxone) and population (Conducted in Turkey),
3 Imprecision due to small sample size
4 Indirectness of: 1) comparison (compared benzyl penicillin gentamicin versus amoxicillin/clavulanate), 2) population (India),
5 Imprecision due to small sample size
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There is no explicitly defined preferred method for taking
these factors into account. Our pragmatic approach was
to engage a national guideline development forum
attended by a panel of 70 people from academic and pol-
icy backgrounds and routine clinical settings. After pre-
senting and discussing the evidence we invited discussion
on these contextual considerations (Figure 2) amongst
panelists to inform development of recommendations
rather than relying on research data alone. However, this
forum did not include patient representatives as is
recommended in GRADE [38], instead professional
health workers were asked to consider this perspective.
Such an approach is pragmatic but has clear limitations.
However, gaining patients’ perspectives, particularly
when they are children, is a poorly developed area of
practice and research in both low and high income set-
tings alike. How this forum and deliberative process pro-
ceeded will be described in detail elsewhere, however
here we illustrate how the evidence met with contrasting
fates in the process of making recommendations.
Most notable was a strong recommendation against the
proposal to adopt oral amoxicillin in place of or even as
an alternative to benzyl penicillin/ampicillin for severe
pneumonia. This was despite evidence from three large
trials suggesting equivalence between the treatments and
several additional factors apparently favoring oral amoxi-
cillin including lower cost, more convenient twice daily
dosing and reduction in the use of injections in children.
In this case the panel essentially discounted moderate
quality evidence and felt that such a change in policy
should only be informed by locally-generated data. Such
an absolute rejection of evidence gathered from trials
involving almost 5000 children, something of a surprise to
those summarizing it, was also observed for other guide-
line topics. In this particular case one could speculate that
the absence of patient views, children who might receive
either multiple injections or oral therapy, might have been
an important omission.
Interestingly, strong recommendations were also made
against proposals to adopt penicillin plus gentamicin for
severe pneumonia and ceftriaxone for very severe pneu-
monia. Although evidence was largely absent, and thus
did not support these proposals, such regimens were
admitted to be common local practice. Here a major rea-
son given for strongly rejecting what was already being
practiced, in support of existing recommendations, was
the perceived need to preserve the alternative treatments
as second line regimens in the absence of viable alterna-
tives. It is thus possible that here discussions on the
absence of evidence supporting superiority of non-guide-
line regimens being used in practice may have helped to
rebuild confidence in existing guidelines. In line with the
evidence presented, the panel made a strong
recommendation to abandon chloramphenicol as an
alternative treatment to benzyl penicillin/ampicillin and
gentamicin for very severe pneumonia. In this case,
although the decision was consistent with the moderate
quality evidence, much of the data summarized was from
non-African children. This contrasts with rejection of
similar quality evidence, also from non-African children,
referred to above in the case of amoxicillin in severe
pneumonia. In this case we speculate that abandoning
chloramphenicol may have resonated with existing views
that the drug was no longer suitable, having been aban-
doned by western countries many years ago on the
grounds of safety.
Discussion
We used the GRADE system to review and contextualize
the evidence on a number of topics as part of an effort to
revise Kenyan national guidelines. We have used the anti-
biotic treatment of community-acquired pneumonia in
Kenyan children to illustrate the approach and some of
the challenges encountered. Perhaps one of the most strik-
ing findings is the limited availability of high quality
evidence generalizable to the population of interest, Ken-
yan or African children. Whereas it is not feasible for all
policies to have supporting data from large randomized
controlled trials, we noted a serious shortage of good evi-
dence on a number of other important guideline related
questions in pediatric and neonatal care. This contrasts
with the situation for a topic such as outpatient malaria,
where a recent systematic review managed to include fifty
randomized trials [39], reflecting the disparities in interest
and funding in child and newborn health.
Where studies are few limitations of the evidence are
likely to be greatest. It is hard to detect publication bias,
inconsistency is clearly hard to evaluate, imprecision is
likely and indirectness related to study site will be com-
mon. With low quality data recommendations should gen-
erally be weak if the GRADE system is adhered to. We
employed a voting system based on an adaptation of the
GRADE grid [40] that it was anticipated would allow the
consensus group to indicate strong or weak support for a
recommendation. However, in almost all cases strong
recommendations were made irrespective of the evidence
quality. While the decision making process might have
influenced this observation we speculate that it may also
reflect concern that a weak recommendation does not
make for a good national guideline.
Grading the evidence when resources are limited may
depend, to a considerable degree, on the subjective deci-
sions of a small number of people. In our case evidence
was summarized and graded by only two to three people.
In an attempt to engage the local pediatric establishment
review teams included people with very limited prior
training or experience in this field. While the GRADE
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after limited introductory training, decisions on how to
g r a d et h eq u a l i t yo fe v i d e n c e ,f o re x a m p l ed o w n - g r a d i n g
for indirectness, might have influenced subsequent
recommendations and inexperience resulting in inap-
propriate decisions may have been important. The alter-
native of engaging a team of experienced methodologists
in an effort to minimize the potential limitations referred
to above would have been associated with substantial
increases in the cost of the process challenging the feasi-
bility of this exercise in low income settings [41]. Instead
we attempted to minimize the potential for error and
bias through adopting measures such as having two
authors independently generate GRADE evidence profiles
and facilitating a transparent reporting of the reviews.
T h eG R A D Ea p p r o a c hp r o m o t e sam o r et r a n s p a r e n t
contextualization of evidence to produce final recom-
mendations. The degree to which it is reasonable to
‘abandon’ evidence in favor of context is perhaps debata-
ble. It appeared to us that moderate quality evidence was
on occasions influential and on others ignored. Thus in
the absence of likely significant additional contextual fac-
tors (such as costs or feasibility) decisions appeared to be
based largely on the preferences of the people assembled
and their views on patient preferences. The dynamics of
the group process, the choice of the discussion modera-
tor and his interaction with the recommendations panel,
the composition of this panel, the mode of presentation
of the evidence and other factors may all have contribu-
ted to the direction and strength of final recommenda-
tions [42-44]. We will report observations on these
potentially important aspects of the use of GRADE in
real life settings in full in due course.
Although our application of the GRADE system may
have implications for the validity of our final recommen-
dations, it can be argued that our approach was in fact an
improvement on previous exercises in national guideline
development that lacked transparency [45]. Previously,
the local process involved the adaptation of recommen-
dations issued by the WHO through a relatively closed
process by a small panel of local experts [41]. The weak-
nesses of this practice were compounded further by flaws
in the process guideline development at the WHO [46].
As more groups in low income settings use GRADE open
sharing of resources and experiences is likely to gain
importance, hence all the material we generated in this
exercise is freely available online [18]. Such sharing of
r e v i e w si si m p o r t a n tt oa v o i dduplication of efforts and
should help set priorities for undertaking and disseminat-
ing formal systematic reviews. Sharing lessons from users
of GRADE will also be valuable for the further refine-
ment and adaptation of this system to optimize guideline
development in settings where the capacity is limited and
locally generated evidence lacking.
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